Clinical Trials Logo

Liver Graft Dysfunction clinical trials

View clinical trials related to Liver Graft Dysfunction.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT01781195 Recruiting - Clinical trials for Liver Graft Dysfunction

Delayed CNI-based Immunosuppression With Advagraf After MELD-based Liver Transplantation

IMUTECT
Start date: February 2013
Phase: N/A
Study type: Observational

Prolonged-release low-dose Advagraf should better protect from CNI-side effects compared to standard immunosuppressive regiments while the rate of rejection is not increased and thus graft function is well maintained. We hypothesize that especially in high-MELD (MELD-score >20) recipients who have a decreased immune competence the prolonged-release low-dose Advagraf concept would better protect from side effects of immunosuppression (i.e. infection). Nevertheless, we assume that also patients with a MELD-score ≤20 will benefit from this concept in regard to lower infection rates and less side effects of immunosuppression.